Daniele Caracciolo

机构：Magna Graecia University, Dulbecco Telethon Institute · ORCID：0000-0001-7870-7565

发表论文 191 篇 · 总被引 6182 次 · h-index 44

代表论文

• miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review (2022 · Molecular Therapy — Nucleic Acids · 被引 161)
• Safety and activity of the first-in-class locked nucleic acid (LNA) miR-221 selective inhibitor in refractory advanced cancer patients: a first-in-human, phase 1, open-label, dose-escalation study (2023 · Journal of Hematology & Oncology · 被引 80)
• Efficacy and safety of first-line checkpoint inhibitors-based treatments for non-oncogene-addicted non-small-cell lung cancer: a systematic review and meta-analysis (2022 · ESMO Open · 被引 44)
• The New Microtubule-Targeting Agent SIX2G Induces Immunogenic Cell Death in Multiple Myeloma (2022 · International Journal of Molecular Sciences · 被引 36)
• miR-22 Modulates Lenalidomide Activity by Counteracting MYC Addiction in Multiple Myeloma (2021 · Cancers · 被引 34)
• The emerging scenario of immunotherapy for T-cell Acute Lymphoblastic Leukemia: advances, challenges and future perspectives (2023 · Experimental Hematology and Oncology · 被引 30)